Analytical Data
-
基因名
HLA-A*02:01&B10M&Survivin(TLPPAWQPFL) Monomer
- Application
-
别名
BIRC5; API4; EPR-1; Baculoviral Inhibitor Of Apoptosis Repeat Containing 5; Apoptosis Inhibitor 4; Survivin Variant 3 Alpha
-
种属
Mouse
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 95% as determined by SDS-PAGE.
-
蛋白编号
O70201
-
表达区间
Met1~Ala140
-
分子量
25kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of HLA-A*02:01, specifically its complex with the peptide survivin (TLPPAWQPFL), focuses on understanding the immune response to cancer. HLA-A*02:01 is one of the most prevalent class I human leukocyte antigens (HLAs) and plays a critical role in presenting intracellular peptides to CD8+ T cells, which are essential for cytotoxic immune responses. Survivin, an important regulator of apoptosis and a component of the chromosomal passenger complex, is often overexpressed in various tumors, making it an attractive target for cancer immunotherapy. The monomeric recombinant protein of HLA-A*02:01 bound to the survivin peptide facilitates detailed studies of T cell recognition and interaction, thereby aiding in the identification of effective therapeutic strategies. By examining this complex, researchers aim to elucidate the mechanisms of immune recognition and to develop peptide-based vaccines or adoptive T cell therapies that could potentially enhance anti-tumor immunity in HLA-A*02:01 positive patients. This research is crucial for advancing personalized cancer treatment and improving patient outcomes through innovative immunotherapeutic approaches.
